Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02955940
Title An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Recruitment Enrolling by invitation
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

Advanced Solid Tumor

Therapies

Ruxolitinib

Capecitabine + Regorafenib

Capecitabine + Regorafenib + Ruxolitinib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.